611 W. Union Street
Benson, AZ 85602
(520) 586-0800

Health Choice Integrated Care crisis Line
1-877-756-4090

NurseWise 24-Hour Crisis Line
1-866-495-6735

NAZCARE Warm Line
1-888-404-5530



SEABHS
611 W. Union Street
Benson, AZ 85602
(520) 586-0800

NurseWise 24-Hr Crisis Line
1-866-495-6735

NAZCARE Warm Line
1-888-404-5530


powered by centersite dot net

Getting Started
Here are some forms to get started. These can be printed and brought with you so that you can pre-fill out some known info ahead of time. More...


Addictions
Resources
Basic Information
What is Addiction?What Causes Addiction?How Do You Get Addicted?Signs and Symptoms of AddictionTreatment for AddictionReferencesResourcesFrequentlly Asked Questions about Addiction
TestsLatest News
Do Energy Drinks + Booze = More Injuries?7 in 10 U.S. Workplaces Hit by Opioid Abuse: SurveySome Docs May Help Fuel Opioid Abuse EpidemicNIAAA Two-Question Alcohol Screen Valid in Pediatric ERsScientists Spot 'Teetotaler' GeneDiscussing Opioid Risks With Patients Reduces MisuseU.S. Surgeon General Declares War on AddictionOpioid Epidemic Costs U.S. $78.5 Billion Annually: CDCSmokers' Perceptions May Play Role in AddictionFDA: Opioids Plus Sedatives Pose Fatal OD RiskAlcohol, Obesity Could Raise Esophageal Cancer RiskSmoke Less, Drink Less?Programs to Spot Painkiller Abuse Work, But Are UnderusedTighter Opioid Laws in U.S. Haven't Eased MisusePatients Often Prescribed Extra Painkillers, Many Share ThemNew Synthetic Drug Linked to Dozens of Deaths Across U.S.Many Addicts Going Without Meds That Curb Opioid AbuseLong-Term Pot Use Tied to Gum Disease in StudyProbuphine Implant Approved for Opioid DependenceHepatitis C Patients More Likely to Drink, Study FindsMarriage a Buffer Against Drinking Problems?More Bars, More Ambulance CallsStoned Stoners OK With Driving While HighChronic Pain May Trigger Many Cases of Painkiller Addiction: SurveyPot-Linked Fatal Car Crashes Doubled in One State After LegalizationAddicts Using Diarrhea Drug Imodium to Get HighPainkiller Addiction Relapse More Likely for SomeOpioid Painkiller May Be New Treatment for Heroin AddictsGenetic Factors Associated With Cannabis Dependence IdentifiedGenes May Link Risks for Pot Use, DepressionObama Administration Steps Up Efforts to Beat Painkiller, Heroin Epidemic
Questions and AnswersLinksBook ReviewsSelf-Help Groups
Related Topics

Anxiety Disorders
Depression: Depression & Related Conditions
Post-Traumatic Stress Disorder

Probuphine Implant Approved for Opioid Dependence

HealthDay News
by -- Scott Roberts
Updated: May 26th 2016

THURSDAY, May 26, 2016 (HealthDay News) -- The U.S. Food and Drug Administration has approved the first-ever buprenorphine implant to treat opioid dependence, the agency said Thursday in a news release.

Up to now, the drug buprenorphine has only been available in pill or film form to be placed under a person's tongue, the FDA said. Probuphine, which provides a constant, low-level dose of the drug, is designed to last six months.

Earlier this year, an FDA advisory committee of experts recommended Probuphine's approval, the agency said.

The drug, combined with behavioral therapy, can combat opioid addiction without "causing the cycle of highs and lows associated with opioid misuse or abuse," and can make the addictive qualities of opioid use less attractive, the FDA said. The agency cited U.S. government statistics that opioid addicts receiving this combined therapy cut their risk of death from all causes by half.

Probuphine's four one-inch rods are surgically implanted under the skin of the upper arm. If additional treatment is needed, a second set of rods may subsequently be implanted in the opposite arm. The agency said it has ordered post-marketing studies of the safety and effectiveness of this additional course of treatment.

Sixty-three percent of people who used Probuphine had no evidence of illicit opioid use throughout the six months of treatment, the agency said.

The label includes a boxed warning of potential dangers during the product's insertion or removal, the FDA said. These include the potential risks of implant protrusion and nerve damage.

Probuphine is marketed by San Francisco-based Titan Pharmaceuticals and Princeton, N.J.-based Braeburn Pharmaceuticals.

More information

Learn more from the FDA.